INTERVENTION 1:	Intervention	0
Test Group	Intervention	1
group	CHEBI:24433	5-10
intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.	Intervention	2
palonosetron	CHEBI:85161	27-39
solution	CHEBI:75958	129-137
day	UO:0000033	142-145
Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)	Intervention	3
dexamethasone	CHEBI:41879	5-18
day	UO:0000033	43-46
fosnetupitant/ palonosetron: intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination	Intervention	4
palonosetron	CHEBI:85161	15-27
palonosetron	CHEBI:85161	56-68
dexamethasone: Oral dexamethasone (12 mg)	Intervention	5
dexamethasone	CHEBI:41879	0-13
dexamethasone	CHEBI:41879	20-33
INTERVENTION 2:	Intervention	6
Control Group	Intervention	7
group	CHEBI:24433	8-13
oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.	Intervention	8
day	UO:0000033	72-75
Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)	Intervention	9
dexamethasone	CHEBI:41879	5-18
day	UO:0000033	43-46
netupitant/palonosetron: oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination	Intervention	10
dexamethasone: Oral dexamethasone (12 mg)	Intervention	11
dexamethasone	CHEBI:41879	0-13
dexamethasone	CHEBI:41879	20-33
Inclusion Criteria:	Eligibility	0
Cycle 1:	Eligibility	1
The following inclusion criteria must be checked prior to inclusion at Cycle 1:	Eligibility	2
Patient read, understood and signed the written informed consent before any study related activity, agreeing to participate in the study and to comply with study requirements.	Eligibility	3
patient	HADO:0000008,OAE:0001817	0-7
Female patient of at least 8 years of age.	Eligibility	4
female	PATO:0000383	0-6
patient	HADO:0000008,OAE:0001817	7-14
age	PATO:0000011	38-41
Histologically or cytologically confirmed breast cancer, including recurrent or metastatic.	Eligibility	5
breast cancer	DOID:1612	42-55
recurrent	HP:0031796	67-76
Na√Øve to moderately or highly emetogenic antineoplastic agents.	Eligibility	6
Scheduled to receive at least 4 consecutive cycles of an AC combination regimen.	Eligibility	7
Notes:	Eligibility	8
additional not emetogenic, minimally or low emetogenic antineoplastic agents are permitted at any time after start of AC combination on Day 1.	Eligibility	9
time	PATO:0000165	98-102
day	UO:0000033	136-139
additional highly or moderately emetogenic antineoplastic agents are only allowed on Day 1 after the start of AC combination, provided their administration is completed within 6 hours from the start of the AC combination administration.	Eligibility	10
day	UO:0000033	85-88
ECOG Performance Status of 0 or 1.	Eligibility	11
Patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to dose of investigational product.	Eligibility	12
patient	HADO:0000008,OAE:0001817	0-7
urine	UBERON:0001088	143-148
product	BAO:0003067	213-220
Notes:	Eligibility	13
Female patients of non-childberaring potential are defined as being in post-menopausal state since at least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before study participation.	Eligibility	14
female	PATO:0000383	0-6
year	UO:0000036	110-114
Reliable contraceptive measures include implants, injectables, combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence;	Eligibility	15
Hematologic and metabolic status adequate for receiving a cycle of AC chemotherapy based on investigator's assessment.	Eligibility	16
If the patient has a known hepatic or renal impairment, she may be enrolled in the study at the discretion of the Investigator.	Eligibility	17
patient	HADO:0000008,OAE:0001817	7-14
Able to read, understand, follow the study procedure and complete the patient diary.	Eligibility	18
patient	HADO:0000008,OAE:0001817	70-77
All inclusion criteria will be checked at screening visit (Visit 1 of Cycle 1); inclusion criteria 7 will be re-checked at Day 1 (Visit 2).	Eligibility	19
day	UO:0000033	123-126
Cycles 2 to 4:	Eligibility	20
The following inclusion criteria must be checked prior to inclusion at each repeated cycle:	Eligibility	21
Participation in the study during the next cycle of chemotherapy is considered appropriate by the Investigator and does not pose unwarranted risk to the patient.	Eligibility	22
patient	HADO:0000008,OAE:0001817	153-160
Scheduled to receive an AC chemotherapy regimen or AC chemotherapy together with other chemotherapies as defined in Inclusion criterion #5 for Cycle 1.	Eligibility	23
Patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to dosing of investigational product.	Eligibility	24
patient	HADO:0000008,OAE:0001817	0-7
urine	UBERON:0001088	143-148
product	BAO:0003067	215-222
Adequate hematologic and metabolic status for receiving a cycle of AC chemotherapy according to the Investigator's opinion.	Eligibility	25
All inclusion criteria will be checked at screening visit (Visit 1); inclusion criterion #3 will be re-checked at Day 1 (Visit 2).	Eligibility	26
day	UO:0000033	114-117
Exclusion Criteria:	Eligibility	27
Cycle 1:	Eligibility	28
The following exclusion criteria must be checked prior to inclusion at Cycle 1:	Eligibility	29
Lactating patient.	Eligibility	30
patient	HADO:0000008,OAE:0001817	10-17
Current use of illicit drugs or current evidence of alcohol abuse.	Eligibility	31
alcohol	CHEBI:16236	52-59
Scheduled to receive moderately or highly emetogenic antineoplastic agent in addition to the AC regimen, from 6 hours after the start of the AC chemotherapy on Day 1 and up to Day 1 of Cycle 2.	Eligibility	32
antineoplastic agent	CHEBI:35610	53-73
day	UO:0000033	160-163
day	UO:0000033	176-179
Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to the start of AC chemotherapy administration on Day 1 or between Days 1 to 5, inclusive.	Eligibility	33
abdomen	UBERON:0000916	61-68
week	UO:0000034	92-96
day	UO:0000033	153-156
day	UO:0000033	170-173
Any vomiting, retching, or nausea (grade 1 as defined by National Cancer Institute) within 24 hours prior to the start of AC chemotherapy administration on Day 1.	Eligibility	34
vomiting	HP:0002013	4-12
nausea	HP:0002018	27-33
cancer	DOID:162	66-72
day	UO:0000033	156-159
Symptomatic primary or metastatic central nervous system (CNS) malignancy.	Eligibility	35
central nervous system	UBERON:0001017	34-56
Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any illness or medical conditions (other than malignancy) that, in the opinion of the Investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting [CINV]) or pose unwarranted risks in administering the study drugs to the patient.	Eligibility	36
active peptic ulcer disease	DOID:749	0-27
gastrointestinal obstruction	HP:0004796	29-57
increased intracranial pressure	HP:0002516	59-90
hypercalcemia	HP:0003072,DOID:12678	92-105
active	PATO:0002354	0-6
active	PATO:0002354	110-116
nausea	HP:0002018	321-327
nausea	HP:0002018	361-367
nausea and vomiting	HP:0002017	361-380
patient	HADO:0000008,OAE:0001817	455-462
Known hypersensitivity or contraindication to 5 hydroxytryptamine type 3 (5-HT3) receptor antagonists (e.g., palonosetron, ondansetron, granisetron, dolasetron, tropisetron, ramosetron), to dexamethasone, or to neurokinin-1 (NK1) receptor antagonists (e.g., aprepitant, rolapitant).	Eligibility	37
hypersensitivity	GO:0002524,DOID:1205	6-22
contraindication	OAE:0000055	26-42
receptor	BAO:0000281	81-89
receptor	BAO:0000281	230-238
palonosetron	CHEBI:85161	109-121
ondansetron	CHEBI:7773	123-134
granisetron	CHEBI:5537	136-147
dolasetron	CHEBI:4682	149-159
tropisetron	CHEBI:32269	161-172
ramosetron	CHEBI:135156	174-184
dexamethasone	CHEBI:41879	190-203
aprepitant	CHEBI:499361	258-268
rolapitant	CHEBI:90908	270-280
Known contraindication to the IV administration of 50 mL 5% glucose solution.	Eligibility	38
contraindication	OAE:0000055	6-22
glucose	CHEBI:4167,BAO:0000924	60-67
solution	CHEBI:75958	68-76
Participation in a previous clinical trial involving IV fosnetupitant or oral netupitant administered alone or in combination with palonosetron.	Eligibility	39
netupitant	CHEBI:85155	59-69
netupitant	CHEBI:85155	78-88
palonosetron	CHEBI:85161	131-143
Any investigational drugs taken within 4 weeks prior to Day 1, and/or is scheduled to receive any investigational drug (other than those planned by the study protocol) during the present study.	Eligibility	40
day	UO:0000033	56-59
drug	CHEBI:23888	20-24
drug	CHEBI:23888	114-118
present	PATO:0000467	179-186
Systemic corticosteroid therapy within 72 hours prior to the start of AC chemotherapy administration on Day 1, except the dexamethasone provided as additional study drug. However, topical and inhaled corticosteroids are permitted.	Eligibility	41
corticosteroid	CHEBI:50858	9-23
corticosteroid	CHEBI:50858	200-214
day	UO:0000033	104-107
dexamethasone	CHEBI:41879	122-135
drug	CHEBI:23888	165-169
Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy during the study participation.	Eligibility	42
bone marrow	UBERON:0002371	21-32
Other than as administered as part of the study protocol, any medication with known or potential antiemetic activity within 24 hours prior to the start of AC chemotherapy administration on Day 1, including:	Eligibility	43
part of	BAO:0090002,BFO:0000050	30-37
antiemetic	CHEBI:50919	97-107
day	UO:0000033	189-192
5-HT3 receptor antagonists (e.g., ondansetron, granisetron, dolasetron, tropisetron, ramosetron, palonosetron)	Eligibility	44
receptor	BAO:0000281	6-14
ondansetron	CHEBI:7773	34-45
granisetron	CHEBI:5537	47-58
dolasetron	CHEBI:4682	60-70
tropisetron	CHEBI:32269	72-83
ramosetron	CHEBI:135156	85-95
palonosetron	CHEBI:85161	97-109
NK1 receptor antagonists (e.g., aprepitant, fosaprepitant, rolapitant or any other new drug of this class)	Eligibility	45
receptor	BAO:0000281	4-12
aprepitant	CHEBI:499361	32-42
aprepitant	CHEBI:499361	47-57
fosaprepitant	CHEBI:64321	44-57
rolapitant	CHEBI:90908	59-69
drug	CHEBI:23888	87-91
benzamides (e.g., metoclopramide, alizapride)	Eligibility	46
benzamides	CHEBI:22702	0-10
metoclopramide	CHEBI:107736	18-32
phenothiazines (e.g., prochlorperazine, promethazine, fluphenazine, perphenazine, thiethylperazine, chlorpromazine)	Eligibility	47
phenothiazines	CHEBI:38093	0-14
prochlorperazine	CHEBI:8435	22-38
promethazine	CHEBI:8461	40-52
fluphenazine	CHEBI:5123	54-66
perphenazine	CHEBI:8028	68-80
thiethylperazine	CHEBI:9544	82-98
chlorpromazine	CHEBI:3647	100-114
benzodiazepines (except if the subject is receiving such medication for sleep or anxiety and has been on a stable dose for at least seven days prior to Day 1).	Eligibility	48
sleep	GO:0030431	72-77
anxiety	HP:0000739,DOID:2030	81-88
stable	HP:0031915	107-113
day	UO:0000033	138-141
day	UO:0000033	152-155
butyrophenones (e.g., haloperidol, droperidol)	Eligibility	49
haloperidol	CHEBI:5613	22-33
droperidol	CHEBI:4717	35-45
anticholinergics (e.g., scopolamine, with the exception of inhaled anticholinergics for respiratory disorders, e.g., ipratropium bromide)	Eligibility	50
scopolamine	CHEBI:16794	24-35
ipratropium bromide	CHEBI:5957	117-136
antihistamines (e.g., cyclizine, hydroxyzine, diphenhydramine, chlorpheniramine)	Eligibility	51
cyclizine	CHEBI:3994	22-31
hydroxyzine	CHEBI:5818	33-44
diphenhydramine	CHEBI:4636	46-61
domperidone	Eligibility	52
domperidone	CHEBI:31515	0-11
mirtazapine	Eligibility	53
mirtazapine	CHEBI:6950	0-11
olanzapine	Eligibility	54
olanzapine	CHEBI:7735	0-10
prescribed cannabinoids (e.g., tetrahydrocannabinol or nabilone)	Eligibility	55
nabilone	CHEBI:135574	55-63
Over The Counter (OTC) antiemetics, OTC cold or OTC allergy medications.	Eligibility	56
allergy	HP:0012393	52-59
Scheduled to receive any strong or moderate inhibitor of CYP3A4 during the efficacy assessment period (Day 1 to Day 5, inclusive) or its intake within 1 week prior to Day 1.	Eligibility	57
moderate	HP:0012826	35-43
inhibitor	CHEBI:35222	44-53
efficacy	BAO:0000656	75-83
day	UO:0000033	103-106
day	UO:0000033	112-115
day	UO:0000033	167-170
week	UO:0000034	153-157
Scheduled to receive any CYP3A4 inducer during the efficacy assessment period (Day 1 to Day 5, inclusive) or its intake within 4 weeks prior to Day 1, with the exception of corticosteroids (for which exclusion criterion #12 applies).	Eligibility	58
inducer	BAO:0003058	32-39
efficacy	BAO:0000656	51-59
day	UO:0000033	79-82
day	UO:0000033	88-91
day	UO:0000033	144-147
History or predisposition to cardiac conduction abnormalities, except for incomplete right bundle branch block.	Eligibility	59
history	BFO:0000182	0-7
cardiac conduction	GO:0061337	29-47
right bundle branch block	HP:0011712,DOID:13209	85-110
History of risk factors for Torsades de Pointes (heart failure, hypokalemia, family history of Long QT Syndrome).	Eligibility	60
history	BFO:0000182	0-7
history	BFO:0000182	84-91
heart	UBERON:0000948	49-54
hypokalemia	HP:0002900,DOID:4500	64-75
family history	HP:0032316	77-91
long qt syndrome	DOID:2843	95-111
Severe or uncontrolled cardiovascular diseases, including myocardial infarction within 3 months prior to Day 1, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial hypertension.	Eligibility	61
severe	HP:0012828	0-6
severe	HP:0012828	314-320
myocardial infarction	HP:0001658,DOID:5844	58-79
day	UO:0000033	105-108
angina pectoris	HP:0001681	121-136
disease	DOID:4,OGMS:0000031	38-45
disease	DOID:4,OGMS:0000031	174-181
history	BFO:0000182	183-190
ventricular tachycardia	HP:0004756	194-217
congestive heart failure	HP:0001635,DOID:6000	231-255
heart	UBERON:0000948	242-247
heart	UBERON:0000948	271-276
hypertension	HP:0000822,DOID:10763	343-355
All exclusion criteria with the exception of criteria #5, #12, and #14 will be checked at screening visit (Visit 1). Exclusion criteria #5, #12, and #14 will be checked at Day 1 (Visit 2) only.	Eligibility	62
day	UO:0000033	172-175
Exclusion criteria #3, #4, #7, #11, #13, #15, and #16 need to be re-checked at Day 1 (Visit 2).	Eligibility	63
day	UO:0000033	79-82
Cycles 2 to 4:	Eligibility	64
The following exclusion criteria must be checked prior to inclusion at each repeated cycle:	Eligibility	65
Scheduled to receive moderately or highly emetogenic antineoplastic agent in addition to the AC regimen, from 6 hours after the start of the AC chemotherapy on Day 1 of current cycle and up to Day 1 of the next cycle.	Eligibility	66
antineoplastic agent	CHEBI:35610	53-73
day	UO:0000033	160-163
day	UO:0000033	193-196
Active infection or uncontrolled disease that may pose unwarranted risks in administering the study drugs to the patient.	Eligibility	67
active	PATO:0002354	0-6
disease	DOID:4,OGMS:0000031	33-40
patient	HADO:0000008,OAE:0001817	113-120
Started any of the prohibited medications.	Eligibility	68
Any vomiting, retching, or nausea (grade ‚â• 1 as defined by National Cancer Institute) within 24 hours prior to the start of AC chemotherapy administration on Day 1.	Eligibility	69
vomiting	HP:0002013	4-12
nausea	HP:0002018	27-33
cancer	DOID:162	68-74
day	UO:0000033	158-161
Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to the start of AC chemotherapy administration on Day 1 or between Days 1 to 5.	Eligibility	70
abdomen	UBERON:0000916	61-68
week	UO:0000034	92-96
day	UO:0000033	153-156
day	UO:0000033	170-173
Symptomatic primary or metastatic CNS malignancy.	Eligibility	71
Any illness or medical condition that, in the opinion of the investigator, may confound the results of the study or pose unwarranted risks in administering the investigational product or dexamethasone to the patient.	Eligibility	72
condition	PDRO:0000129	23-32
product	BAO:0003067	176-183
dexamethasone	CHEBI:41879	187-200
patient	HADO:0000008,OAE:0001817	208-215
All exclusion criteria, with exception of criterion #4, will be checked at screening visit (Visit 1). Exclusion criterion #4 will be checked at Day 1 (Visit 2) only. Exclusion criteria #2, #3 and #5 need to be re-checked at Day 1 (Visit 2).	Eligibility	73
day	UO:0000033	144-147
day	UO:0000033	224-227
Outcome Measurement:	Results	0
Number of Participants With Treatment-emergent AEs at Cycle 1	Results	1
[Not Specified]	Results	2
Time frame: At the end of Cycle 1 (each cycle is 21 days)	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Test Group	Results	5
group	CHEBI:24433	4-9
group	CHEBI:24433	22-27
Arm/Group Description: intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.	Results	6
palonosetron	CHEBI:85161	50-62
solution	CHEBI:75958	152-160
day	UO:0000033	165-168
Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)	Results	7
dexamethasone	CHEBI:41879	5-18
day	UO:0000033	43-46
fosnetupitant/ palonosetron: intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination	Results	8
palonosetron	CHEBI:85161	15-27
palonosetron	CHEBI:85161	56-68
dexamethasone: Oral dexamethasone (12 mg)	Results	9
dexamethasone	CHEBI:41879	0-13
dexamethasone	CHEBI:41879	20-33
Overall Number of Participants Analyzed: 200	Results	10
Measure Type: Count of Participants	Results	11
Unit of Measure: Participants  121  60.5%	Results	12
Results 2:	Results	13
Arm/Group Title: Control Group	Results	14
group	CHEBI:24433	4-9
group	CHEBI:24433	25-30
Arm/Group Description: oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.	Results	15
day	UO:0000033	95-98
Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)	Results	16
dexamethasone	CHEBI:41879	5-18
day	UO:0000033	43-46
netupitant/palonosetron: oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination	Results	17
dexamethasone: Oral dexamethasone (12 mg)	Results	18
dexamethasone	CHEBI:41879	0-13
dexamethasone	CHEBI:41879	20-33
Overall Number of Participants Analyzed: 202	Results	19
Measure Type: Count of Participants	Results	20
Unit of Measure: Participants  122  60.4%	Results	21
Adverse Events 1:	Adverse Events	0
Total: 5/200 (2.50%)	Adverse Events	1
Anaemia * 1/200 (0.50%)	Adverse Events	2
Neutropenia * 1/200 (0.50%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
Febrile neutropenia * 0/200 (0.00%)	Adverse Events	4
neutropenia	HP:0001875,DOID:1227	8-19
Atrial fibrillation * 0/200 (0.00%)	Adverse Events	5
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Vomiting * 1/200 (0.50%)	Adverse Events	6
vomiting	HP:0002013	0-8
Pyrexia * 1/200 (0.50%)	Adverse Events	7
Biliary colic * 1/200 (0.50%)	Adverse Events	8
Urinary tract infection * 1/200 (0.50%)	Adverse Events	9
urinary tract infection	DOID:0080784	0-23
Clostridium difficile colitis * 0/200 (0.00%)	Adverse Events	10
clostridium difficile colitis	HP:0032168,DOID:0060185	0-29
Erysipelas * 1/200 (0.50%)	Adverse Events	11
erysipelas	HP:0001055,DOID:11330	0-10
Adverse Events 2:	Adverse Events	12
Total: 4/202 (1.98%)	Adverse Events	13
Anaemia * 1/202 (0.50%)	Adverse Events	14
Neutropenia * 1/202 (0.50%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	0-11
Febrile neutropenia * 1/202 (0.50%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	8-19
Atrial fibrillation * 1/202 (0.50%)	Adverse Events	17
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Vomiting * 0/202 (0.00%)	Adverse Events	18
vomiting	HP:0002013	0-8
Pyrexia * 0/202 (0.00%)	Adverse Events	19
Biliary colic * 0/202 (0.00%)	Adverse Events	20
Urinary tract infection * 1/202 (0.50%)	Adverse Events	21
urinary tract infection	DOID:0080784	0-23
Clostridium difficile colitis * 1/202 (0.50%)	Adverse Events	22
clostridium difficile colitis	HP:0032168,DOID:0060185	0-29
Erysipelas * 0/202 (0.00%)	Adverse Events	23
erysipelas	HP:0001055,DOID:11330	0-10
